drugset / Trial / NCT00513188
Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma
Withdrawn
University of Miami
Treatment
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Combinations of biological substances in denileukin diftitox may be able to carry cancer-killing substances directly to non-Hodgkin lymphoma cells. Giving combination chemotherapy together with denileukin diftitox may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving combination chemotherapy together with denileukin diftitox works in treating patients with newly diagnosed T-cell non-Hodgkin lymphoma.
Timeline
- Start
- 2007-02
- Primary completion
- 2008-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Cytarabine | Small molecule | — | Intravenous |
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Leucovorin | Small molecule | — | Intravenous |
| Subject | Methotrexate | Small molecule | — | Intravenous |
| Subject | Prednisone | Other / unclassified | — | Oral |
| Subject | Vincristine | Small molecule | — | Intravenous |
| Subject | denileukin diftitox | Protein / enzyme biologic | — | Intravenous |